Stillwater Capital Advisors LLC lessened its position in Johnson & Johnson (NYSE:JNJ) by 0.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,601 shares of the company’s stock after selling 886 shares during the quarter. Johnson & Johnson accounts for approximately 3.3% of Stillwater Capital Advisors LLC’s portfolio, making the stock its 8th largest holding. Stillwater Capital Advisors LLC’s holdings in Johnson & Johnson were worth $13,241,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stuart Chaussee & Associates Inc. boosted its position in Johnson & Johnson by 20.7% during the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after buying an additional 80 shares during the period. Selective Wealth Management purchased a new stake in Johnson & Johnson during the third quarter valued at about $105,000. Ifrah Financial Services Inc. purchased a new stake in Johnson & Johnson during the third quarter valued at about $203,000. First Capital Advisors Group LLC. purchased a new stake in Johnson & Johnson during the third quarter valued at about $207,000. Finally, Jentner Corp purchased a new stake in Johnson & Johnson during the third quarter valued at about $208,000. 67.32% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have issued reports on the stock. BMO Capital Markets upped their price target on shares of Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $151.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 17th. Raymond James increased their target price on shares of Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 target price for the company in a report on Wednesday, March 27th. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus target price of $146.40.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 35.79%. Johnson & Johnson’s revenue for the quarter was up .1% on a year-over-year basis. During the same period in the prior year, the business posted $2.06 earnings per share. Research analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Stillwater Capital Advisors LLC Trims Position in Johnson & Johnson (JNJ)” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/johnson-johnson-jnj-is-stillwater-capital-advisors-llcs-8th-largest-position.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is a put option?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.